Aug 12 (Reuters) - Mabwell Shanghai Bioscience Co Ltd 688062.SS:
MABWELL ANNOUNCES FIRST PATIENT DOSED IN THE US CLINICAL STUDY OF BULUMTATUG FUVEDOTIN IN TNBC PATIENTS PREVIOUSLY TREATED WITH ADCS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.